^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cretostimogene grenadenorepvec (CG0070)

    i
    Company:
    CG Oncology, Kissei
    Drug class:
    GM-CSF agonist, Cell death stimulant
    Related drugs:
    Apply
    Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC (MCC-20575) (NCT04610671)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2020
    Primary completion :
    01/18/2025
    Completion :
    01/01/2026
    CD8
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • cisplatin • cretostimogene grenadenorepvec (CG0070)
    Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure (BOND2) (NCT02365818)
    Phase 2
    CG Oncology, Inc.
    Completed
    Last update posted :
    04/14/2021
    Initiation :
    06/02/2015
    Primary completion :
    08/01/2018
    Completion :
    02/01/2019
    PD-L1 • PD-1
    |
    cretostimogene grenadenorepvec (CG0070)